Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2022 wishlist
    • Media room
    • Latest news
    • Jobs
    Wishlist 2020
    Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19
      • Explainer: A bold proposal at the WTO by India and South Africa
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
      • Explainer: COVID-19 vaccines - Recommendations for equitable access
      • Share the Tech - Save Lives
    Wishlist 2020
    Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • No Patents in a Pandemic
      • 20 years of Advocacy in Action
      • Share the Tech - Save Lives
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Newsletters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    • Blog
    Wishlist 2020
    🌟Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2022 wishlist
    • Media room
    • Latest news
    • Jobs
    Wishlist 2020
    Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19
      • Explainer: A bold proposal at the WTO by India and South Africa
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
      • Explainer: COVID-19 vaccines - Recommendations for equitable access
      • Share the Tech - Save Lives
    Wishlist 2020
    Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • No Patents in a Pandemic
      • 20 years of Advocacy in Action
      • Share the Tech - Save Lives
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Newsletters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    • Blog
    Wishlist 2020
    🌟Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action!
Get involved
Share the Tech - Save Lives Share the Tech

The African continent is one of the regions most affected by vaccine shortages. We need to urgently address this inequity.

South African activists protest in support of the WTO TRIPS Waiver No Patents, No Monopolies in a Pandemic

Help us tell governments blocking the movement to speed up equitable access to COVID-19 vaccines, tests and treatments to put lives over profit.

MSF Access Campaign

NEW: MSF response to @Gavi’s intent to purchase @Sanofi-@GSK #COVID19 #vaccine candidate for the COVAX Facility⬇️ bit.ly/3my565j

00:23 - 29 Oct 2020
Navigate
  • About the Access Campaign
  • 1999-2019: 20 Years of Advocacy in Action
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access Campaign
Médecins Sans Frontières
Rue de Lausanne 78
P.O Box 1016
CH-1211 Geneva 1, Switzerland
Phone:+41 22 849 8484 Fax:+41 22 849 8404
E-mail: access(at)msf.org

Follow us on Twitter and Facebook
  • Twitter
  • Vimeo
  • Facebook
Medicines Shouldn't Be A Luxury